BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 20203261)

  • 1. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.
    Swords RT; Kelly KR; Smith PG; Garnsey JJ; Mahalingam D; Medina E; Oberheu K; Padmanabhan S; O'Dwyer M; Nawrocki ST; Giles FJ; Carew JS
    Blood; 2010 May; 115(18):3796-800. PubMed ID: 20203261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.
    Khalife J; Radomska HS; Santhanam R; Huang X; Neviani P; Saultz J; Wang H; Wu YZ; Alachkar H; Anghelina M; Dorrance A; Curfman J; Bloomfield CD; Medeiros BC; Perrotti D; Lee LJ; Lee RJ; Caligiuri MA; Pichiorri F; Croce CM; Garzon R; Guzman ML; Mendler JH; Marcucci G
    Leukemia; 2015 Oct; 29(10):1981-92. PubMed ID: 25971362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.
    Milhollen MA; Traore T; Adams-Duffy J; Thomas MP; Berger AJ; Dang L; Dick LR; Garnsey JJ; Koenig E; Langston SP; Manfredi M; Narayanan U; Rolfe M; Staudt LM; Soucy TA; Yu J; Zhang J; Bolen JB; Smith PG
    Blood; 2010 Sep; 116(9):1515-23. PubMed ID: 20525923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
    Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S
    Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine.
    Nawrocki ST; Kelly KR; Smith PG; Keaton M; Carraway H; Sekeres MA; Maciejewski JP; Carew JS
    Clin Cancer Res; 2015 Jan; 21(2):439-47. PubMed ID: 25388161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924.
    Blank JL; Liu XJ; Cosmopoulos K; Bouck DC; Garcia K; Bernard H; Tayber O; Hather G; Liu R; Narayanan U; Milhollen MA; Lightcap ES
    Cancer Res; 2013 Jan; 73(1):225-34. PubMed ID: 23100467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.
    Smith MA; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Morton CL; Wu J; Smith PG; Yu J; Houghton PJ
    Pediatr Blood Cancer; 2012 Aug; 59(2):246-53. PubMed ID: 22012946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells.
    Godbersen JC; Humphries LA; Danilova OV; Kebbekus PE; Brown JR; Eastman A; Danilov AV
    Clin Cancer Res; 2014 Mar; 20(6):1576-89. PubMed ID: 24634471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.
    Soucy TA; Smith PG; Milhollen MA; Berger AJ; Gavin JM; Adhikari S; Brownell JE; Burke KE; Cardin DP; Critchley S; Cullis CA; Doucette A; Garnsey JJ; Gaulin JL; Gershman RE; Lublinsky AR; McDonald A; Mizutani H; Narayanan U; Olhava EJ; Peluso S; Rezaei M; Sintchak MD; Talreja T; Thomas MP; Traore T; Vyskocil S; Weatherhead GS; Yu J; Zhang J; Dick LR; Claiborne CF; Rolfe M; Bolen JB; Langston SP
    Nature; 2009 Apr; 458(7239):732-6. PubMed ID: 19360080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cells.
    Xu GW; Toth JI; da Silva SR; Paiva SL; Lukkarila JL; Hurren R; Maclean N; Sukhai MA; Bhattacharjee RN; Goard CA; Medeiros B; Gunning PT; Dhe-Paganon S; Petroski MD; Schimmer AD
    PLoS One; 2014; 9(4):e93530. PubMed ID: 24691136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer.
    Nawrocki ST; Kelly KR; Smith PG; Espitia CM; Possemato A; Beausoleil SA; Milhollen M; Blakemore S; Thomas M; Berger A; Carew JS
    Clin Cancer Res; 2013 Jul; 19(13):3577-90. PubMed ID: 23633453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of tumor angiogenesis by targeting the protein neddylation pathway.
    Yao WT; Wu JF; Yu GY; Wang R; Wang K; Li LH; Chen P; Jiang YN; Cheng H; Lee HW; Yu J; Qi H; Yu XJ; Wang P; Chu YW; Yang M; Hua ZC; Ying HQ; Hoffman RM; Jeong LS; Jia LJ
    Cell Death Dis; 2014 Feb; 5(2):e1059. PubMed ID: 24525735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor.
    Wei D; Li H; Yu J; Sebolt JT; Zhao L; Lawrence TS; Smith PG; Morgan MA; Sun Y
    Cancer Res; 2012 Jan; 72(1):282-93. PubMed ID: 22072567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ.
    Brownell JE; Sintchak MD; Gavin JM; Liao H; Bruzzese FJ; Bump NJ; Soucy TA; Milhollen MA; Yang X; Burkhardt AL; Ma J; Loke HK; Lingaraj T; Wu D; Hamman KB; Spelman JJ; Cullis CA; Langston SP; Vyskocil S; Sells TB; Mallender WD; Visiers I; Li P; Claiborne CF; Rolfe M; Bolen JB; Dick LR
    Mol Cell; 2010 Jan; 37(1):102-11. PubMed ID: 20129059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of glioblastoma by targeting the overactivated protein neddylation pathway.
    Hua W; Li C; Yang Z; Li L; Jiang Y; Yu G; Zhu W; Liu Z; Duan S; Chu Y; Yang M; Zhang Y; Mao Y; Jia L
    Neuro Oncol; 2015 Oct; 17(10):1333-43. PubMed ID: 25904638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression.
    Jia L; Li H; Sun Y
    Neoplasia; 2011 Jun; 13(6):561-9. PubMed ID: 21677879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overactivated neddylation pathway as a therapeutic target in lung cancer.
    Li L; Wang M; Yu G; Chen P; Li H; Wei D; Zhu J; Xie L; Jia H; Shi J; Li C; Yao W; Wang Y; Gao Q; Jeong LS; Lee HW; Yu J; Hu F; Mei J; Wang P; Chu Y; Qi H; Yang M; Dong Z; Sun Y; Hoffman RM; Jia L
    J Natl Cancer Inst; 2014 Jun; 106(6):dju083. PubMed ID: 24853380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of NEDD8 NEDDylation induced apoptosis in acute myeloid leukemia cells via p53 signaling pathway.
    Chen Y; Sun L
    Biosci Rep; 2022 Aug; 42(8):. PubMed ID: 35880551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The NEDD8-activating enzyme inhibitor MLN4924 induces G2 arrest and apoptosis in T-cell acute lymphoblastic leukemia.
    Han K; Wang Q; Cao H; Qiu G; Cao J; Li X; Wang J; Shen B; Zhang J
    Oncotarget; 2016 Apr; 7(17):23812-24. PubMed ID: 26993774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The NEDD8-activating enzyme inhibition with MLN4924 sensitizes human cancer cells of different origins to apoptosis and necroptosis.
    El-Mesery M; Anany MA; Hazem SH; Shaker ME
    Arch Biochem Biophys; 2020 Sep; 691():108513. PubMed ID: 32721435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.